0
0
0
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
8/1/2024, 12:40 PM
Summary of Bill S 4905
Bill 118 s 4905, also known as the Pediatric Cancer Targeted Therapy Act, aims to make important changes to the Federal Food, Drug, and Cosmetic Act in order to improve the investigation and treatment of pediatric cancer. The bill specifically focuses on the use of molecularly targeted therapies, which are treatments that target specific molecules within cancer cells to stop the growth and spread of the disease.
One of the key provisions of the bill is to encourage the development and testing of molecularly targeted therapies for pediatric cancer. This includes providing incentives for pharmaceutical companies to conduct clinical trials specifically focused on pediatric patients. By doing so, the bill aims to increase the availability of effective treatments for children with cancer.
Additionally, the bill seeks to improve the coordination and communication between the Food and Drug Administration (FDA), National Institutes of Health (NIH), and other relevant agencies when it comes to pediatric cancer research. This will help ensure that promising treatments are identified and brought to market in a timely manner. Overall, the Pediatric Cancer Targeted Therapy Act is a bipartisan effort to address the unique challenges faced by children with cancer and to improve their access to cutting-edge treatments. By focusing on molecularly targeted therapies and promoting collaboration among key stakeholders, the bill has the potential to make a significant impact on the lives of pediatric cancer patients and their families.
One of the key provisions of the bill is to encourage the development and testing of molecularly targeted therapies for pediatric cancer. This includes providing incentives for pharmaceutical companies to conduct clinical trials specifically focused on pediatric patients. By doing so, the bill aims to increase the availability of effective treatments for children with cancer.
Additionally, the bill seeks to improve the coordination and communication between the Food and Drug Administration (FDA), National Institutes of Health (NIH), and other relevant agencies when it comes to pediatric cancer research. This will help ensure that promising treatments are identified and brought to market in a timely manner. Overall, the Pediatric Cancer Targeted Therapy Act is a bipartisan effort to address the unique challenges faced by children with cancer and to improve their access to cutting-edge treatments. By focusing on molecularly targeted therapies and promoting collaboration among key stakeholders, the bill has the potential to make a significant impact on the lives of pediatric cancer patients and their families.
Current Status of Bill S 4905
Bill S 4905 is currently in the status of Bill Introduced since July 31, 2024. Bill S 4905 was introduced during Congress 118 and was introduced to the Senate on July 31, 2024.  Bill S 4905's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S5685-5686) as of July 31, 2024
Bipartisan Support of Bill S 4905
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
2Democrat Cosponsors
0Republican Cosponsors
2Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 4905
Primary Policy Focus
Alternate Title(s) of Bill S 4905
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.
Comments
Sponsors and Cosponsors of S 4905
Latest Bills
Ending Discrimination in Government Contracting Act
Bill HR 8511May 14, 2026
Ending Discrimination in Government Contracting Act
Bill S 4390May 14, 2026
To designate the facility of the United States Postal Service located at 201 East Grant Avenue in Georgetown, Ohio, as the "Ulysses S. Grant Post Office Building".
Bill HR 7809May 14, 2026
To designate the facility of the United States Postal Service located at 111 South Tremont Street in Tremonton, Utah, as the "Sorensen-Estrada Post Office".
Bill HR 8225May 14, 2026
To designate the facility of the United States Postal Service located at 189 East Main Street in Xenia, Ohio, as the "Gilman 'Gil' Whitney Post Office Building".
Bill HR 8193May 14, 2026
To designate the facility of the United States Postal Service located at 2200 South Salina Street in Syracuse, New York, as the "Wallie Howard Jr. Post Office Building".
Bill HR 6099May 14, 2026
To designate the facility of the United States Postal Service located at 3817 Marysville Boulevard in Sacramento, California, as the "Grantland Johnson Post Office".
Bill HR 2488May 14, 2026
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Bulletin 2022-06: Unfair Returned Deposited Item Fee Assessment Practices".
Bill HJRES 171May 14, 2026
Supporting the mission and goals of National Fentanyl Awareness Day in 2026, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
Bill HRES 1234May 14, 2026
A resolution supporting the mission and goals of National Fentanyl Awareness Day in 2026, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people.
Bill SRES 704May 14, 2026